<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is the predominant gastrointestinal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> and the leading cause of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The identification of genes related to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> is important for the development of successful therapies and earlier diagnosis </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Molecular analysis of feces was evaluated as a potential method for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> detection </plain></SENT>
<SENT sid="3" pm="."><plain>Expression of a predicted protein with unknown function, KIAA0247, was found in feces evaluated using specific quantitative real-time polymerase chain reaction </plain></SENT>
<SENT sid="4" pm="."><plain>Its cellular function was then analyzed using immunofluorescent staining and the changes in the cell cycle in response to <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (5-FU) were assessed </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Gastrointestinal tissues and peripheral blood lymphocytes ubiquitously expressed KIAA0247 </plain></SENT>
<SENT sid="6" pm="."><plain>56 CRC patients fell into two group categories according to fecal KIAA0247 <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression levels </plain></SENT>
<SENT sid="7" pm="."><plain>The group with higher fecal KIAA0247 (n=22; ≥0.4897) had a significantly greater five-year overall survival rate than the group with lower fecal KIAA0247 (n = 30; &lt;0.4897) (66.0 ± 11.6%; p=0.035, log-rank test) </plain></SENT>
<SENT sid="8" pm="."><plain>Fecal expression of KIAA0247 inversely related to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> size (Kendall's tau-b=-0.202; p=0.047) </plain></SENT>
<SENT sid="9" pm="."><plain>Immunofluorescent staining revealed that the cytoplasm of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells evenly expresses KIAA0247 without 5-FU treatment, and KIAA0247 accumulates in the nucleus after 40 μM 5-FU treatment </plain></SENT>
<SENT sid="10" pm="."><plain>In HCT116 p53(-/-) cells, which lack p53 cell cycle control, the proportion of cells in the G2/M phase was larger (13%) in KIAA0247-silent cells than in the respective shLuc control (10%) and KIAA0247-overexpressing cells (7%) after the addition of low dose (40 μM) 5-FU </plain></SENT>
<SENT sid="11" pm="."><plain>Expression of three cyclin genes (cyclin A2, cyclin B1, and cyclin B2) also downregulated in the cells overexpressing KIAA0247 </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: This is the first description of a linkage between KIAA0247 and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>The study's data demonstrate overexpression of KIAA0247 associates with 5-FU therapeutic benefits, and also identify the clinical significance of fecal KIAA0247 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>